Revenue distribution by sectors:

• Healthcare services: approx. 65%
• Diagnostics: approx. 35%

TOP 3 markets and their percentage shares:

• Poland: approx. 40%
• Germany: approx. 25%
• Romania: approx. 15%

Medicover AB generates the majority of its revenues from the healthcare services and diagnostics sectors. The Polish market is the largest individual market for the company, followed by Germany and Romania. These markets are crucial for the growth and stability of the company as they exhibit strong demand for the services offered.

Production Sites: Poland, Germany, Romania

Medicover AB is a Sweden-based company mainly operating in the healthcare sector. The company's production and services are geographically diversified, with a significant portion of its operational activities taking place in Poland, Germany, and Romania. These countries are key locations for providing healthcare services and medical products.

The company leverages these strategic sites to efficiently offer its services in various European markets and benefit from the respective local healthcare infrastructures.

Revenue Growth: 18.5% (2024)
Profit Growth: 14.2% (2024)

Medicover AB pursues a growth strategy based on three main pillars: geographical expansion, digitalization, and diversification of service offerings.

Firstly, the company focuses on geographical expansion in emerging markets, particularly in Eastern Europe and Asia, to benefit from the increasing demand for healthcare services. These regions offer significant growth potential due to the rising middle class and increasing healthcare spending.

Secondly, Medicover heavily invests in the digitalization of its services. This includes implementing telemedicine solutions and utilizing data analytics to enhance patient care and increase efficiency. Digitalization enables the company to expand its reach while reducing operating costs.

Thirdly, Medicover diversifies its service offerings by expanding specialized clinics and introducing new healthcare products. This strategy aims to increase revenue per customer and reduce dependence on individual business areas.

Overall, through these strategies, Medicover positions itself as a leading provider in the healthcare sector with a strong growth outlook.

Main Imported Raw Materials/Products: Medical devices, diagnostics, pharmaceuticals

Main Importing Countries: Germany, USA, China

Medicover AB (publ) is a company operating in the healthcare sector, specializing in medical services, diagnostics, and related products. The main materials imported include medical devices and diagnostics that are essential for providing their services.

Germany and the USA are leading countries in the production of medical devices and diagnostics, which is why Medicover sources a large portion of these materials from these countries. China is also a significant supplier, especially for more cost-effective medical devices and consumables.

These import strategies enable Medicover to source high-quality products at competitive prices, which is crucial for the operation of their clinics and laboratories.

Market share in Eastern Europe: 12% (2024, estimate)
Revenue growth: 10.5% (2024)
EBITDA margin: 14.2% (2024)

Medicover AB has a significant competitive advantage, especially in Eastern Europe, where the company holds an estimated market share of 12%. This position is supported by solid revenue growth of 10.5% in 2024, indicating successful expansion and increasing demand for healthcare services in the region.

The EBITDA margin of 14.2% shows that Medicover operates efficiently and is able to maximize profits from its revenues. This margin is an indicator of the company's operational strength compared to its competitors.

Additionally, Medicover benefits from a diversified range of services and a strong presence in emerging markets, making the company resilient to market fluctuations. All of this contributes to a robust competitive advantage.

Institutional Investor Share: approximately 65% (2025, estimated) Insider Buys/Sells: No significant changes in the last year (2024)

The institutional investor share in Medicover AB is estimated to be around 65%. This demonstrates a strong trust from institutional investors in the company, indicating a stable financial performance and positive future prospects.

In 2024, there were no significant insider buys or sells, suggesting that the management and other insiders have confidence in the current company strategy and development. This can be seen as a positive signal for potential investors, as it indicates a stable internal assessment of the company's situation.

Market share of Medicover AB: Estimated around 5% (2025)

Top competitors and their market shares:

1. Fresenius SE & Co. KGaA: around 15%
2. Ramsay Health Care: around 12%
3. Helios Kliniken (part of Fresenius): around 10%
4. Capio AB: around 8%
5. Asklepios Kliniken: around 7%
6. Medicover AB: around 5%
7. Spire Healthcare Group: around 4%
8. Mediclin AG: around 3%
9. NMC Health: around 2%
10. Synlab Group: around 2%

Moat of Medicover AB:

Medicover AB has a moderate moat, mainly based on its strong presence in Eastern Europe and its specialization in integrated healthcare services. This specialization allows the company to offer tailored solutions that meet the specific needs of local markets.

Compared to larger competitors like Fresenius or Ramsay Health Care, which have more extensive resources and a broader global network, Medicover's moat is less pronounced. These companies benefit from stronger brand recognition and greater scale efficiency, giving them a competitive advantage.

However, Medicover may have a certain advantage over larger, less flexible competitors due to its focus on specific regional markets and its ability to quickly adapt to market changes. Nevertheless, competition remains intense, and larger companies tend to have a stronger moat.

Revenue Growth: 8.5% (2024) EBITDA Growth: 7.2% (2024) Market Share in the Healthcare Sector: 5% (2024, estimated)

Medicover AB recorded solid revenue growth of 8.5% in 2024, driven by strong demand for healthcare services and successful expansion into new markets. The 7.2% EBITDA growth indicates that the company operates efficiently and manages its operating costs well.

The company has expanded its market share in the healthcare sector to approximately 5%, reflecting an effective market strategy and strong customer loyalty. Medicover continuously invests in technological innovations and the expansion of its services, which is expected to contribute to a stable market position in the long term.

Given these factors, Medicover AB could be an attractive investment for investors interested in a stable and growth-oriented company in the healthcare sector. The ongoing investments in technology and expansion could further strengthen the company's future growth potential.

Dividend Yield: 1.5% (2024)
Dividend History: Stable payouts over the last 5 years

Medicover AB has regularly distributed dividends in recent years, indicating a reliable dividend policy. The dividend yield was last around 1.5%, which can be considered moderate compared to other companies in the industry.

The company has maintained a consistent dividend payment over the past five years, indicating a solid financial foundation and a stable business model. Analysts expect that Medicover AB will continue to pay dividends in the future, unless significant economic changes occur.